Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Current Leases (2020 - 2025)

Apellis Pharmaceuticals has reported Current Leases over the past 6 years, most recently at $7.1 million for Q4 2025.

  • Quarterly results put Current Leases at $7.1 million for Q4 2025, up 4.95% from a year ago — trailing twelve months through Dec 2025 was $7.1 million (up 4.95% YoY), and the annual figure for FY2025 was $7.1 million, up 4.95%.
  • Current Leases for Q4 2025 was $7.1 million at Apellis Pharmaceuticals, up from $7.0 million in the prior quarter.
  • Over the last five years, Current Leases for APLS hit a ceiling of $7.4 million in Q2 2025 and a floor of $3.9 million in Q1 2021.
  • Median Current Leases over the past 5 years was $5.8 million (2023), compared with a mean of $5.8 million.
  • Biggest five-year swings in Current Leases: skyrocketed 51.46% in 2021 and later rose 3.39% in 2025.
  • Apellis Pharmaceuticals' Current Leases stood at $4.1 million in 2021, then skyrocketed by 36.7% to $5.6 million in 2022, then grew by 14.51% to $6.4 million in 2023, then grew by 4.84% to $6.8 million in 2024, then increased by 4.95% to $7.1 million in 2025.
  • The last three reported values for Current Leases were $7.1 million (Q4 2025), $7.0 million (Q3 2025), and $7.4 million (Q2 2025) per Business Quant data.